Hedge funds run it up to sky high prices,sell when it can't go any higher and then short it to the bottom. You are better off owning large drug companies that pay good dividends. Merck,Pfizer,Bristol Myers, etc
Did they put too much capital into too few product trials.
Compared to other companies BIIB trials numbers look weak:
BIIB 50 studies found for : Biogen | Open Studies | Exclude Unknown
AMGN 101 studies found for: AMGEN | Open Studies | Exclude Unknown
GILD 130 studies found for: GILEAD | Open Studies | Exclude Unknown
LLY: 173 studies found for: ELI LILLY | Open Studies | Exclude Unknown
SNY: 177 studies found for: SANOFI | Open Studies | Exclude Unknown
GSK: 291 studies found for: GlaxoSmithKline | Open Studies | Exclude Unknown
AZN: 348 studies found for: AstraZeneca | Open Studies | Exclude Unknown
PFE: 373 studies found for: Pfizer | Open Studies | Exclude Unknown
MRK: 414 studies found for: Merck | Open Studies | Exclude Unknown
JNJ: 569 studies found for: Johnson & Johnson | Open Studies | Exclude Unknown
Lovin' the opportunities at these levels. Like picking up nuggets of gold on the ground! Takes brass balls to buy here though. Not for the faint of heart.
Buy BIIB(BIOGEN IDEC Inc.)
Take profit as soon as it hits $248.86.The target is valid for next one week
This prediction is based on TinoIQ Proprietary algorithm
Probability of trade success calculated is : 99.38%.
TINO's machine learning predictive analytic algorithms analyzes thousands of stocks everyday and performs billions of calculations on last 25 years of data to predict only the best stocks for trade.
Keep looking for future algorithm based results.
Ouch......I totally agree with your sentiment and reasoning. Most of my holdings are in treasuries with the exception of my shorts that are doing very well. Once the dust settles I am hoping to be able to jump in and capture some nice gains that have eluded the market over the past year.
This stock has been oversold for the last year. It will either need to acquire another company soon or it will be acquired. No doubt in my mind.
BIIB is a good company with cash producing products today. However, pipeline is not there and growth will be slow if at all in the next couple of years. Unless they acquire. So this puppy should trade at a relatively low multiple.
You are comparing biotech to gold? That's a silly comparison as they have nothing in common. You can compare anything to anything using your logic. Omit.
More importantly these ivory tower players have gambled Trillions of dollars with the future of the US and simply have no clue nor credibility...I can train a monkey to do what these people have done!!!